Chronic Lymphocytic Leukemia — An Interview with Dr Lindsey Roeker on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting
Research To Practice | Oncology Videos · Dr. Neil Love
May 25, 202548m 23s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring an interview with Dr Lindsey Roeker, including the following topics:
- Clinical development of novel Bruton tyrosine kinase (BTK) degraders in therapy for chronic lymphocytic leukemia (CLL) (0:00)
- Safety of BTK inhibitors in older and frail patients with CLL (3:41)
- Utility of minimal residual disease-guided treatment with venetoclax/obinutuzumab (9:20)
- Impact of the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab in CLL (16:32)
- Utility of acalabrutinib, venetoclax and obinutuzumab for high-risk CLL (23:31)
- Emerging data with sonrotoclax and zanubrutinib in treatment-naïve CLL (25:16)
- Sequencing, tolerability and future development involving pirtobrutinib (25:57)
- Emerging data with the addition of a BTK inhibitor to chimeric antigen receptor T-cell therapy (32:28)
- Clinical considerations in the management of Richter's transformation (38:14)
- Survival outcomes and quality of life for patients with CLL (41:02)
- Ongoing and future efforts to improve CLL treatment outcomes (45:01)
CME information and select publications